Spruce Biosciences, Inc.
SPRB Healthcare Biotechnology
Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.
Follow SPRB
Spruce Biosciences, Inc. (SPRB) EV/Sales
As of 16 October 2026, Spruce Biosciences, Inc. (SPRB) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from −2.3× (August 2025) to 1,559× (February 2024); the current reading is higher than 59% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 257× | (69.26%) |
| FY2023 | 836× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 257× | 29.06% |
| Sep 2024 | 199× | 21.22% |
| Jun 2024 | 164× | (31.89%) |
| Mar 2024 | 241× | (71.15%) |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OTLK Outlook Therapeutics, Inc. compare | −73.2× |
| ENGN enGene Therapeutics Inc compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. | 1.5× |
| NRXP NRx Pharmaceuticals, Inc. compare | 22.6× |
| ABOS Acumen Pharmaceuticals, Inc. compare | 30.3× |
| HUMA Humacyte, Inc. compare | 40.3× |
| ARMP Armata Pharmaceuticals, Inc. compare | 68.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)